Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18498228 | 0.82 | GRIN2B (0.67) | GRIN2BS1PR1S1PR5FUCA1KMT2A | |
| SCHEMBL5242542 | 0.78 | FUCA1 (0.64) | GRIN2BS1PR1S1PR5FUCA1SIGMAR1 | |
| SCHEMBL18498129 | 0.77 | GRIN2B (0.53) | GRIN2BS1PR1S1PR5FUCA1ALDH1A1 | |
| SCHEMBL18517593 | 0.77 | GRIN2B (0.53) | GRIN2BS1PR1S1PR5FUCA1ALDH1A1 | |
| SCHEMBL21064724 | 0.76 | FUCA1 (0.55) | GRIN2BFUCA1SIGMAR1 | |
| SCHEMBL4692050 | 0.75 | GRIN2B (0.58) | GRIN2BS1PR1S1PR5FUCA1KMT2A | |
| SCHEMBL18498115 | 0.75 | KDM4E (0.40) | KDM4EKMT2ASIGMAR1ALDH1A1TSPO | |
| SCHEMBL7685605 | 0.75 | GRIN2B (0.58) | GRIN2BS1PR1S1PR5FUCA1KMT2A | |
| SCHEMBL18517590 | 0.75 | GRIN2B (0.55) | GRIN2BS1PR1S1PR5FUCA1KMT2A | |
| SCHEMBL12125070 | 0.75 | KDM4E (0.58) | KDM4ES1PR1S1PR5FUCA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3334729-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944613-B2 | Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2018-03-22 | — | — | US | disclosed |
| WO-2017027687-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027687-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND THEIR USE AS METAP2 INHIBITORS | ZAFGEN, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079737-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | GRIN2B 1690/4885KDM4E 3677/4885S1PR1 2867/4885 |
| US-20180237449-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | GRIN2B 1690/4885KDM4E 3677/4885S1PR1 2867/4885 |
| US-20190092781-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | GRIN2B 1690/4885KDM4E 3677/4885S1PR1 2867/4885 |
| US-20190023716-A1 | FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FOLH1, FAP | GRIN2B 1690/4885KDM4E 3677/4885S1PR1 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.